Blood pressure, lipids, metabolic health, liver function, work pressure and sexual health often belong to the same clinical picture.

Cardiovascular disease can develop quietly for years. Its first sign may be a raised blood-pressure reading, a changing waistline, a shifting lipid profile, fatty liver spotted on a scan, poorer exercise tolerance, or a change in erectile function. Each finding deserves attention on its own — but its real meaning only emerges when it's read as part of the wider physiology.

For men, then, a useful cardiovascular review asks more than whether cholesterol is "high" or blood pressure is "normal." It looks at the pressure acting on the artery wall, the particles carrying lipids through the blood, glucose and insulin regulation, visceral fat, liver and kidney health, sleep, work stress, hormonal symptoms, medication and family history — together, as one story rather than several.

Blood pressure and the load on the arteries

Blood pressure is the force generated as the heart pumps blood through the circulation. When it stays elevated, it adds mechanical stress to the arterial lining and extra workload to the heart and kidneys. Over time, this can contribute to arterial stiffness, left-ventricular changes, kidney damage, and a higher risk of stroke and coronary disease.

Hypertension is often symptomless. Headache, flushing or palpitations can arise for many reasons and cannot reliably confirm or rule it out. Even a single clinic reading can be skewed — by pain, anxiety, caffeine, recent exercise, an unsuitable cuff, or simply the clinical setting itself. Repeated home measurements or ambulatory monitoring give a more representative pattern when that's clinically appropriate. Current European guidance places blood pressure within a person's overall cardiovascular risk, rather than judging one number in isolation.

Contributing factors can include family history, age, visceral adiposity, insulin resistance, obstructive sleep apnoea, alcohol, smoking, kidney disease, medication, and chronic psychosocial stress. A raised reading, in other words, calls for a considered assessment — not an assumption about a single cause.

Cholesterol is essential — but its transport matters

Cholesterol is not a waste product. Every cell needs it for membrane structure, and the body uses it to build steroid hormones, bile acids and vitamin D. Most of it is made in the body, with the liver central to its synthesis, recycling and clearance. Diet plays a role — but only one part of the picture.

Because cholesterol and triglycerides don't dissolve in water, they travel through the bloodstream packaged inside lipoproteins. A standard lipid panel measures some of the cholesterol and triglyceride carried within these particles; it does not directly measure how much cholesterol the liver is producing.

• Total cholesterol is the combined cholesterol carried across several lipoprotein classes — difficult to interpret on its own.
• LDL cholesterol estimates the cholesterol contained within LDL particles, but not the number of particles themselves.
• Non-HDL cholesterol, calculated by subtracting HDL from total cholesterol, captures cholesterol carried in LDL and other potentially atherogenic particles, including triglyceride-rich remnants.
• Apolipoprotein B (apoB) estimates the number of atherogenic particles directly — especially informative when LDL looks acceptable but triglycerides, diabetes, insulin resistance or visceral adiposity suggest particle number may still be high.
• Triglycerides reflect another arm of lipid and energy transport. Raised levels may accompany insulin resistance, fatty liver, alcohol intake, certain medicines, genetic disorders, or simply recent food intake.
• HDL cholesterol still has a place in risk assessment, but a high result is no guarantee of protection — deliberately raising HDL has not consistently reduced cardiovascular events.
• Lipoprotein(a) [Lp(a)] is largely genetically determined. Contemporary guidance recommends measuring it at least once in adulthood, since an elevated level adds inherited risk invisible to a routine lipid panel.

Atheroma develops when apoB-containing particles enter and become trapped within the artery wall. The immune and repair response that follows can build a lipid-rich plaque of inflammatory tissue, fibrous tissue and, eventually, calcium. So the real question isn't whether cholesterol is "good" or "bad" — it's what the complete lipid pattern reveals about cumulative exposure and overall risk.

Visceral fat links metabolism, hormones and liver health

Body weight alone tells an incomplete story. Fat stored around the abdominal organs is metabolically active in ways that subcutaneous fat is not. Some men with a high body mass index carry relatively little visceral fat; others with a lower BMI carry more of it around the organs and within the liver itself.

A 2026 analysis of almost 5,000 US men found that visceral adiposity revealed marked testosterone differences even among men within the same BMI or waist category. Men with high visceral fat had substantially lower testosterone than men with low visceral fat — and some normal-weight men with high visceral fat had testosterone levels comparable to men classified as obese.The study was cross-sectional, so it can't prove visceral fat caused the hormonal change — but it shows how easily weight alone can miss something important about male physiology.

Visceral adiposity can increase fatty-acid delivery to the liver and contribute to insulin resistance. Higher insulin, in turn, can reduce hepatic production of sex hormone-binding globulin, which affects measured total testosterone. Adipose aromatase activity, inflammatory signals, leptin dysregulation and sleep apnoea may all add further pressure on the hypothalamic-pituitary-gonadal axis. Lower testosterone then makes it harder to preserve muscle, and may favour further fat accumulation — a cycle that can become self-reinforcing.

None of this means every man carrying abdominal weight has hypogonadism, or that a low testosterone result should automatically lead to replacement therapy. Symptoms, repeated morning measurements and the wider endocrine and metabolic context all matter. Weight-loss studies do show that endogenous testosterone can improve as weight falls, though the response varies between individuals and methods of weight loss.

The liver sits at the centre of this metabolic traffic. Metabolic dysfunction-associated steatotic liver disease (MASLD) describes excess liver fat occurring alongside metabolic risk — and it can be silent, since normal liver enzymes don't always rule it out. MASLD can also appear in people who aren't visibly overweight.

Fatty liver matters for cardiovascular health because it commonly travels with insulin resistance, atherogenic dyslipidaemia, hypertension and systemic inflammation. Recent large prospective research links MASLD — particularly more severe disease — with the development of cardiometabolic disease and multimorbidity.

These studies don't prove liver fat alone causes cardiovascular disease; MASLD is both a marker of shared metabolic disturbance and a possible contributor to it. Fibrosis risk matters especially, so liver assessment may include enzymes, platelet count, an appropriate fibrosis score, and imaging where the clinical picture warrants it.

Work stress and inadequate recovery

"Work stress" deserves more precision than simply "being busy." Research commonly distinguishes job strain — high demands paired with low control — from effort-reward imbalance, where sustained effort goes unmatched by security, recognition, remuneration or progression.

In an 18-year Canadian cohort, men exposed to either job strain or effort-reward imbalance had a 49 per cent higher adjusted incidence of coronary heart disease. Men exposed to both faced roughly double the incidence of those exposed to neither. This was observational, so it can't prove work stress caused each event — but the association held even after adjusting for major clinical and lifestyle factors. A related prospective study also linked these workplace stressors to atrial fibrillation.

The likely pathway isn't a single "cortisol problem." Chronic strain can alter sympathetic activity, blood-pressure regulation and sleep. It can also shape alcohol intake, appetite, food timing, movement, smoking, and even whether someone has the bandwidth to attend appointments or follow a treatment plan. Shift work and obstructive sleep apnoea can compound the strain further.

Assessment should therefore ask about workload, control, recovery, sleep and coping patterns — alongside blood pressure and lab results. Stress-management techniques help, but they can't fully offset an unsafe workload or persistently damaging working conditions.

Erectile difficulty can be a cardiovascular clue

An erection depends on arterial inflow, endothelial signalling, intact nerves, appropriate hormonal support and psychological safety. Persistent or unexplained erectile difficulty can therefore be an early prompt to review cardiovascular and metabolic risk — particularly alongside hypertension, diabetes, smoking, abdominal adiposity, or reduced exercise tolerance.

Recent long-term cohort evidence continues to link erectile dysfunction with cardiovascular mortality, and the Princeton IV consensus recommends folding cardiovascular risk assessment into the care of men presenting with erectile dysfunction. Association isn't causation here: medication, anxiety or depression, relationship factors, low testosterone, neurological disease, pelvic surgery, alcohol and sleep disturbance can all contribute too.

The right response is neither alarm nor dismissal — just a careful history and a proportionate look at the wider picture.

Testosterone treatment needs context

Low testosterone often turns up alongside obesity, diabetes, sleep apnoea, chronic illness and certain medicines. It may reflect organic hypogonadism — or it may simply be a functional signal of poorer metabolic health.

The TRAVERSE randomized trial followed 5,246 men with symptoms, repeatedly low testosterone, and established cardiovascular disease or elevated cardiovascular risk. Over a mean treatment period of roughly 22 months, testosterone wasn't associated with more major cardiovascular events than placebo — but atrial fibrillation, pulmonary embolism and acute kidney injury occurred more often in the testosterone group.[A separate observational analysis of healthy men aged 70 or older linked high-normal endogenous testosterone with more incident atrial fibrillation.

These findings argue against simplistic claims in either direction. Testosterone treatment shouldn't be marketed as cardiovascular prevention — but appropriately prescribed treatment for confirmed hypogonadism shouldn't automatically be painted as dangerous either. Diagnosis, indication, dose, treatment target and monitoring all matter.

Other male health encounters can reveal cardiometabolic risk

Male infertility may sometimes be another early marker. A 2026 population study of more than 445,000 fathers found modestly higher adjusted risks of hypertension, heart disease and diabetes among men diagnosed with infertility. Important lifestyle factors couldn't be fully measured, so infertility shouldn't be called a cause of cardiovascular disease — but a fertility assessment can offer a useful window into metabolic health for men who might otherwise have little contact with healthcare.

Prostate-cancer treatment is another important context. Androgen-deprivation therapy can affect body composition, glucose regulation, lipids and cardiovascular risk. In a small 2026 randomized trial of 62 men receiving radiotherapy and androgen-deprivation therapy, Leuprolide was associated with greater progression of total and non-calcified coronary plaque over 12 months than Relugolix. This shouldn't change cancer treatment without oncology input — but it does support proactive cardiovascular monitoring and shared decision-making, particularly for men with existing risk.

What a useful cardiovascular review may include

No single test captures cardiovascular health, and not everyone needs every investigation. Depending on age, symptoms, history and existing diagnoses, a review may consider:

• repeated clinic, home or ambulatory blood-pressure measurements
• total cholesterol, LDL, HDL, triglycerides and non-HDL cholesterol, with apoB and Lp(a) where appropriate
• fasting glucose or HbA1c and other markers of insulin resistance when relevant
• waist pattern and body composition, not body weight alone
• liver enzymes, platelet count, and assessment for MASLD or fibrosis risk
• kidney function and urine findings
• smoking, alcohol, food pattern, movement and cardiorespiratory fitness
• sleep duration, snoring, daytime sleepiness and possible sleep apnoea
• work strain, mood, recovery and major life pressures
• erectile, hormonal, fertility or prostate-treatment history
• medicines, supplements and family history of premature cardiovascular disease

These results need to be read together. Raised triglycerides, a larger waist, fatty liver and lower SHBG, for instance, may describe one connected metabolic pattern rather than four unrelated problems.

The Wildberry approach

At Wildberry Clinic, we assess cardiovascular health within a person's wider physiological and clinical story — reviewing symptoms, diagnoses, investigations, medication, family history, sleep, food pattern, activity, work demands, metabolic health, and relevant hormonal or sexual-health changes. Where further investigation or medical treatment is needed, we support appropriate discussion with the GP or consultant.

Clinical herbal medicine may have a supportive role in areas such as vascular tone, endothelial function, stress regulation, sleep, metabolic health and liver function. The choice must always be individual — blood pressure, kidney and liver function, prescribed medication and potential herb-drug interactions all shape what's appropriate. Herbal treatment does not replace indicated antihypertensive, lipid-lowering, diabetes, anticoagulant or oncology care.

The arteries may tell their story through a blood-pressure reading or a lipid panel. But they speak just as often through sleep, liver health, abdominal metabolism, work strain, or erectile function. Read together, these signs offer a chance to act — earlier, and more intelligently.

References

1. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45(38):3912–4018. doi:10.1093/eurheartj/ehae178.
2. Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153–e1276. doi:10.1161/CIR.0000000000001423.
3. Friedl KE, Potter AW. Low testosterone is a phenotype of visceral adiposity. Journal of the Endocrine Society. 2026;10(8). doi:10.1210/jendso/bvag160.
4. Muir CA, Wittert GA, Handelsman DJ. Approach to the patient: low testosterone concentrations in men with obesity. Journal of Clinical Endocrinology & Metabolism. 2025;110(9)–e3130. doi:10.1210/clinem/dgaf137.
5. Brzozowska MM, Bliuc D, Mazur A, et al. Sex-differential testosterone response to long-term weight loss. International Journal of Obesity. 2024;48(10):1481–1488. doi:10.1038/s41366-024-01591-7.
6. European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology. 2024;81(3):492–542. doi:10.1016/j.jhep.2024.04.031.
7. Shen C, et al. Metabolic dysfunction-associated steatotic liver disease, cardiometabolic multimorbidity and mortality: evidence from the UK Biobank. Clinical Research in Cardiology. 2026;115(8):1378–1388. doi:10.1007/s00392-026-02845-2.
8. Lavigne-Robichaud M, et al. Psychosocial stressors at work and coronary heart disease risk in men and women: 18-year prospective cohort study of combined exposures. Circulation: Cardiovascular Quality and Outcomes. 2023;16(10). doi:10.1161/CIRCOUTCOMES.122.009700.
9. Tiwa Diffo E, et al. Psychosocial stressors at work and atrial fibrillation incidence: an 18-year prospective study. Journal of the American Heart Association. 2024;13(16). doi:10.1161/JAHA.123.032414.
10. Bhattacharyya S, et al. Association of erectile dysfunction with all-cause and cardiovascular mortality in US men: findings from NHANES 2001–2004 with 16-year follow-up. International Journal of Impotence Research. Published online 24 November 2025. doi:10.1038/s41443-025-01218-z.
11. Kloner RA, Burnett AL, Miner M, et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. The Journal of Sexual Medicine. 2024;21(2):90–116. doi:10.1093/jsxmed/qdad163.
12. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025.
13. Tran C, et al. Testosterone and the risk of incident atrial fibrillation in older men: further analysis of the ASPREE study. eClinicalMedicine. 2024;72:102611. doi:10.1016/j.eclinm.2024.102611.
14. Marozzi J, Hanly M, Venetis C, et al. Male infertility and risk of cardiometabolic conditions: a population-based cohort study. Human Reproduction. 2026;41(1):93–107. doi:10.1093/humrep/deaf218.
15. Patel SA, et al. Coronary plaque progression after androgen deprivation therapy in men with prostate cancer: a randomized clinical trial. JAMA Cardiology. 2026;11(5):459–463. doi:10.1001/jamacardio.2025.5586.

Important information

This article is provided for general educational purposes and is not a substitute for individual medical assessment, diagnosis or treatment. Cardiovascular symptoms, persistent erectile difficulties, suspected testosterone deficiency and abnormal blood-pressure or laboratory results should be assessed by an appropriately qualified healthcare professional.

Do not start, stop or alter prescribed medication, testosterone treatment, supplements or herbal medicines on the basis of this article. Herbal medicines can interact with prescribed medicines and may require particular caution in people with cardiovascular, liver or kidney disease, those taking anticoagulant or antiplatelet medication, and those preparing for surgery.

Clinical herbal care at Wildberry Clinic is intended to work alongside—not replace—care from GPs, consultants and other healthcare professionals.

Chest pain or pressure, sudden breathlessness, fainting, signs of a stroke, or a new rapid or irregular heartbeat accompanied by chest pain, breathlessness or dizziness requires urgent medical assessment. In Ireland, call 112 or 999.